Feasibility of Mosapride to predict enzyme-based drug-drug interactions in rats
碩士 === 國立成功大學 === 臨床藥學與藥物科技研究所 === 100 === Introduction CYP3A is one of the most important and most abundant subfamily expressed in the liver and small intestine. The use of selected drugs as “probes” to assess in vivo CYP activity has been the subject of intense interest for over a decade. Among ma...
Main Authors: | Li-ChiYang, 楊禮綺 |
---|---|
Other Authors: | Chen-Hsi Chou |
Format: | Others |
Language: | zh-TW |
Published: |
2012
|
Online Access: | http://ndltd.ncl.edu.tw/handle/42512722099225907650 |
Similar Items
-
Feasibility of mosapride as an in vivo probe of CYP3A activity in rats
by: Ya-Wen Chang, et al.
Published: (2008) -
Limited sampling strategy to predict AUC of CYP3A phenotyping probe mosapride in rats
by: Ching-yun Wei, et al.
Published: (2009) -
Spectrophotometric determination of mosapride in pure and pharmaceutical preparations
by: H. D. Revanasiddappa, et al.
Published: (2018-09-01) -
Prediction of Severity of Drug-Drug Interactions Caused by Enzyme Inhibition and Activation
by: Alexander Dmitriev, et al.
Published: (2019-10-01) -
Mosapride as a hepatic CYP3A probe in rats: application to rilpivirine pharmacokinetics
by: Wen-HanChen, et al.
Published: (2013)